IVCC/CCSVI, articles et liens de ce mardi.
Barre google de traduction indispensable!
*"
Percutaneous Endovascular Procedure Proven Safe and Tolerable in Patients With MS: Presented at ECTRIMS
By David S. MacDougall
GOTHENBURG, Sweden -- October 17, 2010 -- A minimally invasive endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI) has proven safe and well tolerated in a small group of patients with multiple sclerosis (MS), according to a report presented here at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
CCSVI is a condition characterised by multiple strictures at the level of the main extracranial cerebrospinal venous outflow tracts that may interfere with normal venous drainage. CCSVI has been implicated in the pathophysiology of MS, but the association remains unproven and controversial.
A group of 15 patients with MS were enrolled in a longitudinal pilot study of endovascular treatments described here on October 14 by Paolo Zamboni, MD, Vascular Diseases Center, University of Ferrara, Ferrara, Italy.
All subjects had CCSVI as previously determined by magnetic resonance imaging (MRI) studies, and were treated with standard disease-modifying MS therapies. Half of the patients received immediate endovascular treatment and the other half received delayed endovascular treatment 6 months after study enrolment.
Endovascular treatment consisted of selective venography of the cerebrospinal vasculature complemented by percutaneous balloon dilatation when indicated. All patients were prospectively evaluated with sonography, MRI, and clinical examinations for up to 12 months following endovascular treatment.
No serious adverse events were observed during the study. One patient developed a transitory vasovagal syndrome about 1 hour after endovascular treatment.
Restenosis occurred in 29% of the patients (2 in the immediate endovascular-treatment group and 2 in the delayed endovascular-treatment group) between 3 and 12 months after endovascular treatment. No significant worsening of MRI or clinical features was observed in either group following endovascular treatment.
The T2 lesion number decreased significantly in the delayed endovascular-treatment group during the time between initial study enrolment and the 6-month follow-up after endovascular treatment (P =.0227).
Additional and larger studies are needed to determine the potential role of endovascular treatment in the treatment of patients with MS, Dr. Zamboni concluded.
Funding for this study was provided by Hilarescere Foundation.
[Presentation title: Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. A Longitudinal Pilot Study. Abstract P508]"
*
*"
Community views of proposed new treatments for Multiple Sclerosis (MS)
Survey prepared by the MS Advisory Council (MSAC)
MSAC is a group of people who have Multiple Sclerosis (MS) or who are carers for people with MS. The members of the Council aim to represent the needs and views of people with MS, their carers and families and MSAC reports directly to the Board of Multiple Sclerosis Limited. You can read more about MSAC’s role and the members of the Council at: http://www.mssociety.org.au/advisory-council.asp
This short survey was prepared by MSAC with the aim of gaining a better understanding of community views of proposed new treatments for MS and how people like to access information about such treatments. You are invited to fill in the survey and email your responses to MSAC at Kate.Cherry@msaustralia.org.au by 5pm on Monday October 18th. All responses will be treated absolutely confidentially. A summary of survey results will be posted on the above website.
- Where do you prefer to source information you trust about proposed new treatments for MS, including medications, lifestyle changes or interventions? (please choose up to 3 and mark with a X)
- Neurologist
- GP or other (non neurologist) health care provider
- Newspaper or television reports
- Scientific journals
- MS society websites
- Speaking with friends or family
- Social networking sites or email groups
- Other (please specify)
2. What factors are most important to help you decide whether you would consider trying (or recommending) a proposed new treatment for MS, such as a medication, lifestyle change or intervention? (choose up to 3)
- Safety / possible side effects of the proposed treatment
- Encouragement from someone who found the treatment helpful
- Neurologist advice regarding the treatment
- Advice from other health care professionals
- Financial cost of the treatment
- Advice from friends or family to try the new treatment
- Availability of published, scientific studies supporting the treatment
- Desire to avoid currently available drug therapies for MS
- Other (please specify)
3. Have you heard of the theory that Chronic Cerebrospinal Venous Insufficiency (CCSVI) may be important in MS?
- Yes
- No (thank you, you have finished this survey)
4. Are you (or someone you care for) currently considering undergoing CCSVI treatment for managing MS symptoms?
- Yes
- No
5. Have you, someone you know, or someone you care for already undergone CCSVI treatment to manage MS?
- Yes
- No (thank you, you have finished this survey)
6. Which best describes the response of your (or the person you know) MS symptoms to treatment for CCSVI? (please select one)
- MS symptoms very much improved
- MS symptoms somewhat improved
- No effect on MS symptoms
- MS symptoms somewhat worsened
- MS symptoms very much worsened
7. Which best describes how long any effect of CCSVI on your (or the person you know) MS symptoms lasted? (please select one)
- CCSVI treatment did not influence MS symptoms
- The effect of CCSVI treatment lasted less than 1 week
- The effect of CCSVI treatment lasted between 1 week – 1 month
- The effect of CCSVI treatment lasted between 1 month – 3 months
- The effect of CCSVI treatment lasted more than 3 months
- CCSVI treatment was done less than 3 months ago, but the effect is ongoing at this time
THANK YOU for taking the time to complete this survey! Please email your responses back to MSAC by 5pm Monday 18th October 2010 at Kate.Cherry@msaustralia.org.au"
*
*"
This page has been created to raise funds to help Dean Brousseau travel to Poland for CCSVI treatment. Dean is suffering significantly with Multiple Sclerosis, and this treatment should help to reduce the symptoms.We can now confirm that the benefit will be held Thursday, November 4th at the Waegwoltic club in Halifax. We will post more information here as details become available. The PayPal account is now set up and working. If you want to make a contribution, please check out the “Contribute” tab at the top of the page.
*MS Patients the Real Sufferers
*"
Opinion: Whose interests are being protected?
